Samsung Bioepis
FDA Approves Ontruzant, Biosimilar to Herceptin
Ontruzant was approved for all eligible indications as the reference product: as an adjuvant therapy for ...
JANUARY 22, 2019
FDA Approves Second Biosimilar of Remicade
Renlexis, a TNF blocker, will be indicated for the treatment of adult and pediatric Crohn’s disease, adult ...
APRIL 24, 2017
Load more